BTCY OTC
Biotricity, Inc.
1W: -18.2%
1M: -44.8%
3M: -54.2%
YTD: -80.9%
1Y: -88.9%
3Y: -97.3%
5Y: -99.7%
$0.06
-0.00 (-2.39%)
Weekly Expected Move ±17.4%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$16M
+16.0% ▲
5Y CAGR: +36.4%
Gross Profit
$13M
+22.6% ▲
5Y CAGR: +59.0%
Operating Income
$2M
+169.1% ▲
Net Income
-$2M
+71.5% ▲
EPS (Diluted)
$-0.11
+80.0% ▲
EBITDA
$2M
+152.6% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $8M | $10M | $12M | $14M | $16M |
| YoY Growth | +126.0% | +26.0% | +25.2% | +14.3% | +16.0% |
| Cost of Revenue | $3M | $4M | $4M | $3M | $3M |
| Gross Profit | $5M | $5M | $8M | $11M | $13M |
| Gross Margin | 59.7% | 56.5% | 69.3% | 76.6% | 80.9% |
| R&D Expenses | $3M | $3M | $3M | $2M | $3M |
| SG&A Expenses | $19M | $18M | $15M | $11M | $8M |
| Operating Expenses | $21M | $21M | $17M | $13M | $11M |
| Operating Income | -$17M | -$15M | -$9M | -$2M | $2M |
| Operating Margin | -218.8% | -159.9% | -73.2% | -17.8% | 10.6% |
| Interest Expense | $11M | $3M | $5M | $5M | -$3M |
| Income Before Tax | -$29M | -$19M | -$14M | -$8M | -$2M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$29M | -$19M | -$14M | -$8M | -$2M |
| Net Margin | -380.8% | -193.6% | -116.8% | -61.1% | -15.0% |
| EPS (Diluted) | $-3.99 | $-2.26 | $-1.66 | $-0.55 | $-0.11 |
| EBITDA | -$19M | -$16M | -$9M | -$3M | $2M |
| Shares Outstanding | 8M | 9M | 9M | 22M | 27M |